NikolaosPapadantonakisMDM.Sc, Ph.D
Hematology • Atlanta, GAHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant professor
Dr. Papadantonakis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Rd NE
Winship Cancer Institute
Atlanta, GA 30322
Summary
- Dr. Nikolaos Papadantonakis is a hematologist in Atlanta, GA and is affiliated with Winship Cancer Institute of Emory University.
He received his medical and graduate degrees from University of Crete Medical School.
He specializes in hematologic oncology with a focus on acute leukemias, myeloproliferative neoplasms and myelodysplastic syndromes.
His interests are in clinical trials and translational research.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2013 - 2016
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 2010 - 2013
University of Crete School of Health SciencesClass of 2005
University of GlasgowB.Sc, Molecular Biology, 1995 - 1999
Certifications & Licensure
GA State Medical License 2019 - 2025
AL State Medical License 2016 - 2019
OH State Medical License 2013 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsMolecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements.Tanvi Verma, Nikolaos Papadantonakis, Deniz Peker Barclift, Linsheng Zhang
Cancers. 2024-01-25 - 6 citationsAKR1C3 expression in T acute lymphoblastic leukemia/lymphoma for clinical use as a biomarker.Deepti Reddi, Brandon W Seaton, David Woolston, Lauri Aicher, Luke D Monroe
Scientific Reports. 2022-04-06 - 111 citationsMyeloproliferative neoplasms, version 2.2018 featured Updates to the NCCN guidelinesRuben A. Mesa, Catriona Jamieson, Ravi Bhatia, Michael W. Deininger, Christopher D.M. Fletcher
Journal of the National Comprehensive Cancer Network. 2017-10-01
Abstracts/Posters
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Nikolaos Papadantonakis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary MyelofibrosisNikolaos Papadantonakis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Sy...Nikolaos Papadantonakis, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients wi...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
